At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 2 enrolled
Drug / intervention
MEDI-507 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Renal Allograft Tolerance Through Mixed Chimerism
In Brief
A Phase 2 clinical trial evaluating MEDI-507, Rituximab, and 2 other interventions for End Stage Renal Disease. Completed, enrolled 2 participants across 1 site.
Detailed Summary
This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a haplo-identical related donor. An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartMar 2013
Primary CompletionJun 2018
Study CompletionJun 2020
TodayJul 2026
First PostedJan 31, 2013
Enrollment StartMar 1, 2013
Primary CompletionJun 1, 2018
Study CompletionJun 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 13.4 years ago
Interventions
MEDI-507drug
T-Cell Depleting Agent
Rituximabdrug
B-Cell Depleting Agent
Total Body Irradiationradiation
Bone Marrow Depletion
Thymic Irradiationradiation